Sophiris Bio : To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting

SAN DIEGO and VANCOUVER, British Columbia, May 5, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the 'Company' or 'Sophiris'), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that positive data from its Phase 3 study of topsalysin as a treatment for the symptoms of benign prostatic hyperplasia will be presented as a late breaking poster on May 7, 2016 from 4:00 p.m. to 5:30 p.m. pacific time in the Science and Technology Hall at the 111American Urological Association Annual Meeting.

Abstract No. 16-8385 (LB-S&T-04): 'Prospective, Randomized, Double Blind, Vehicle Controlled, Multinational, Phase 3 Clinical Trial of the Pore Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia (The PLUS-1 Trial)'
Presenting Author: Dr. Claus Roehrborn, UT Southwestern Medical Center
Poster Session: Late-Breaking Science & Technology Poster
Time: May 7, 2016 from 4:00 p.m. to 5:30 p.m. pacific time

The abstract related to the poster can be accessed through the American Urological Association website at http://www.aua2016.org/abstracts/.

About Sophiris

Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin is in Phase 3 clinical development for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin is also currently in a Phase 2a proof of concept study for the treatment of localized low to intermediate risk prostate cancer. For more information, please visit www.sophirisbio.com.

Company Contact:
Peter Slover
Chief Financial Officer
[phone]
Corporate Communications and Investor Relations:
Jason Spark	Michael Moore
Canale Communications	NATIONAL Equicom
Corporate Communications and IR	Investor Relations
[phone]	[phone]
[e-mail]	[e-mail]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sophiris-bio-to-present-topsalysin-phase-3-data-from-positive-plus-1-study-as-a-late-breaking-poster-during-the-111th-american-urological-association-annual-meeting-300263993.html

SOURCE Sophiris Bio Inc.